First Line Hepato Cellular Carcinoma (HCC)
The purpose of this study is to compare the overall survival of brivanib versus sorafenib in subjects with advanced HCC who have not received prior systemic therapy.
Hepato Cellular Carcinoma (HCC)
DRUG: Brivanib|DRUG: Placebo|DRUG: Sorafenib|DRUG: Placebo
To compare the overall survival of brivanib versus sorafenib in subjects with advanced HCC who have not received prior systemic treatment, Survival will be assessed continuously
To compare the time to progression (TTP) (investigator assessed using modified RECIST criteria for HCC, Every 6 weeks|To compare the investigator assessed objective response rate (ORR) and disease control rate (DCR) using modified RECIST criteria for HCC, Every 6 weeks|To determine duration of response, duration of disease control, and time to response (TTR), Every 6 weeks|To assess the safety profile of brivanib and sorafenib, Every 6 weeks|To explore PK and exposure-response in the study population, Every 6 weeks|To compare time to symptomatic progression, Every 6 weeks|To compare health-related quality of life, Every 6 weeks
The purpose of this study is to compare the overall survival of brivanib versus sorafenib in subjects with advanced HCC who have not received prior systemic therapy.